Literature DB >> 12512844

Intensive plasma IgG removal therapy for severe thrombotic thrombocytopenic purpura.

Saori Yasuzawa Amano, Masafumi Inoue, Yataro Yoshida, Hideo Yagi, Hiromichi Ishizashi, Masanori Matsumoto, Yoshihiro Fujimura, Akira Yoshioka.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12512844     DOI： 10.1007/bf02982815

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  8 in total

1.  Intensive plasmapheresis for severe thrombotic thrombocytopenic purpura: long-term clinical outcome.

Authors:  D Rund; T Schaap; S Gillis
Journal:  J Clin Apher       Date:  1997       Impact factor: 2.821

Review 2.  Von Willebrand factor-cleaving protease and Upshaw-Schulman syndrome.

Authors:  Yoshihiro Fujimura; Masanori Matsumoto; Hideo Yagi; Akira Yoshioka; Taei Matsui; Koiti Titani
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

3.  Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura.

Authors:  H M Tsai; L Rice; R Sarode; T W Chow; J L Moake
Journal:  Ann Intern Med       Date:  2000-05-16       Impact factor: 25.391

4.  Upshaw-Schulman syndrome revisited: a concept of congenital thrombotic thrombocytopenic purpura.

Authors:  S Kinoshita; A Yoshioka; Y D Park; H Ishizashi; M Konno; M Funato; T Matsui; K Titani; H Yagi; M Matsumoto; Y Fujimura
Journal:  Int J Hematol       Date:  2001-07       Impact factor: 2.490

5.  Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.

Authors:  H M Tsai; E C Lian
Journal:  N Engl J Med       Date:  1998-11-26       Impact factor: 91.245

6.  von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.

Authors:  M Furlan; R Robles; M Galbusera; G Remuzzi; P A Kyrle; B Brenner; M Krause; I Scharrer; V Aumann; U Mittler; M Solenthaler; B Lämmle
Journal:  N Engl J Med       Date:  1998-11-26       Impact factor: 91.245

7.  United States Thrombotic Thrombocytopenic Purpura Apheresis Study Group (US TTP ASG): multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange.

Authors:  N Bandarenko; M E Brecher
Journal:  J Clin Apher       Date:  1998       Impact factor: 2.821

8.  Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity.

Authors:  Yoshitaka Mori; Hideo Wada; Esteban C Gabazza; Nobuyuki Minami; Tsutomu Nobori; Hiroshi Shiku; Hideo Yagi; Hiromichi Ishizashi; Masanori Matsumoto; Yoshihiro Fujimura
Journal:  Transfusion       Date:  2002-05       Impact factor: 3.157
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.